Open Repository of the University of Porto (University of Porto)
June 5, 2020
Rui Pedro Leal Andrade
Background: Psilocybin is a naturally occurring serotonin receptor agonist that can be, more commonly, found in the Psilocybe mushrooms. Consumed by indigenous cultures for millenia, Psilocybin, in the 1960s, was marketed in many countries under the trade name Indocybin, and, before its eventual ban, was safely used as an adjunct to psychotherapy in the treatment of depression and anxiety....
Frontiers in Psychiatry
June 3, 2020
Alina Wilkowska, Łukasz P. Szałach, Jakub Słupski et al.
9 citations
There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder patient with treatment resistant depressive episode experiencing a switch to manic episode with mixed features shortly after receiving eight...
BMC Psychiatry
June 2, 2020
J. Phillips, N. Jaworska, Elizabeth Kamler et al.
22 citations
Background Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing...
Mindfulness
June 1, 2020
Kristina Sundquist, Karolina Palmér, Ashfaque A. Memon et al.
Abstract Objectives Identification of biological markers that can guide treatment selection is considered to be a viable solution for personalized treatment for patients with psychiatric disorders. This study investigated whether macrophage migration inhibitory factor (MIF) levels at baseline were associated with mindfulness-based group therapy or cognitive behavioral therapy response in...
Trends in Psychiatry and Psychotherapy
June 1, 2020
Aliakbar Foroughi, Kheirollah Sadeghi, Aliakbar Parvizifard et al.
Introduction Depression is one of the most important psychiatric disorders, and the rate of recurrence is high. The heavy cost burden of depression is probably due to treatment-resistant depression. The purpose of this study was to determine the effectiveness of mindfulness-based cognitive therapy (MBCT) in patients with treatment-resistant depression (TRD). Method The present study was a...
Mindfulness
June 1, 2020
Paweł Holas, Izabela Krejtz, Katarzyna Wisiecka et al.
Abstract Objectives Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment to prevent relapse in individuals with recurrent major depressive disorder (MDD). It is not clear if MBCT is an effective therapy for current depression, and it is not clear what mechanisms are responsible for the effectiveness of MBCT. Theoretically, MBCT is believed to modify the processing of...
Journal of Psychedelic Studies
June 1, 2020
Mitch Earleywine, Joseph A. de Leo
12 citations
Abstract Despite the popular support for psychedelics as aids for depression, academics and the public frequently overestimate the efficacy of available medications and psychotherapies. Metaanalyses reveal that antidepressant medications alone help only one in four patients and rarely surpass credible placebos. Their effects, though statistically significant, might not impress depressed...
Frontiers in Integrative Neuroscience
May 28, 2020
Anna Xu, Chloe S. Zimmerman, Sara W. Lazar et al.
Objective: Tai chi (TC), a contemplative practice combining slow movements and deep breathing, has been shown to be clinically effective in alleviating depressive symptoms. Feelings of fatigue or low vitality often accompany major depressive disorder (MDD) though they are commonly overlooked and not well understood neurologically. By using resting state functional connectivity (rs-FC) using the...
Sleep
May 27, 2020
T Shapiro, B Messman, Danica C. Slavish et al.
Abstract: Introduction: Nurses report a higher prevalence of posttraumatic stress disorder (PTSD) than the general population, and approximately 18% of nurses report having depression. Nightmares are a common symptom of PTSD, and both nightmares and PTSD are correlated with depression. Nightmares may represent a possible clinical target for improving outcomes in both disorders. This study...
The Journal of Clinical Psychiatry
May 26, 2020
George I. Papakostas, Naji C. Salloum, Rebecca S. Hock et al.
107 citations
OBJECTIVE: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting intranasal therapy for depression and is currently under development for suicidality. The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). DATA SOURCES: A systematic search of PubMed/MEDLINE was conducted up to January 2019, in addition to...